Navigation Links
Hospira Reports Third-Quarter 2008 Results
Date:11/5/2008

-- Reaffirms 2008 adjusted* earnings projection --

LAKE FOREST, Ill., Nov. 5 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today reported results for the third quarter of 2008.

-- Net sales increased 10.4 percent to $925.5 million during the

third quarter of 2008, compared to $838.0 million during the

third quarter of 2007.

-- Adjusted* diluted earnings per share increased 28.6 percent in the

third quarter to $0.63 compared to $0.49 during the third quarter

last year. GAAP third-quarter 2008 diluted earnings per share were

$0.51 versus $0.37 for the same period last year. (Adjusted* measures

exclude certain specified items as described later in this press

release and attached schedules.)

"We are pleased by the strong growth we achieved during the quarter in our primary areas of strategic focus," said Christopher B. Begley, chairman and chief executive officer. "Both Specialty Injectable Pharmaceuticals and Medication Management Systems posted double-digit sales increases, and each area saw favorable developments that will drive future growth. We remain on track to achieve our 2008 earnings projections and continue to position Hospira for future success."

Third-quarter Financial Highlights

The following table summarizes selected financial results for the quarters ended September 30:

In $ millions GAAP Adjusted*

Three Months Ended Three Months Ended

Sept. 30, Sept. 30,

---------------- % ---------------- %

2008 2007 Change 2008 2007 Change

------ ------ ------ ------ ------ ------

Net Sales $925.5 $838.0 10.4% $925.5 $838.0 10.4%

Gross Profit $330.0 $294.5 12.1% $355.5 $316.5 12.3%

R&D $51.7 $51.4 0.6% $50.8 $50.8 0.0%

SG&A $145.6 $136.5 6.7% $143.2 $129.4 10.7%

Income from

Operations $132.7 $106.6 24.5% $161.5 $136.3 18.5%

Statistics (as a % of Net Sales)

--------------------------------

Gross Profit 35.7% 35.1% 38.4% 37.8%

R&D 5.6% 6.1% 5.5% 6.1%

SG&A 15.7% 16.3% 15.5% 15.4%

Income from

Operations 14.3% 12.7% 17.5% 16.3%

Results under U.S. Generally Accepted Accounting Principles (GAAP) include items as detailed in the schedules attached to this release.

Net sales for the third quarter of 2008 increased 10.4 percent compared to the third quarter of 2007. The primary contributors were strong sales in Specialty Injectable Pharmaceuticals coupled with increased demand for the company's Medication Management Systems product lines. Net sales for the third quarter of 2008 increased in all segments compared to the third quarter of 2007: the Americas; Europe, Middle East and Africa (EMEA); and Asia Pacific (APAC) increased 9.5 percent, 9.6 percent and 23.0 percent, respectively.

Adjusted* income from operations for the third quarter of 2008 was $161.5 million, up 18.5 percent compared to the third quarter of 2007. The increase was driven by improved adjusted* gross profit performance, partially offset by an increase in adjusted* Selling, General and Administrative (SG&A) expenses. Adjusted* SG&A grew due to increased sales and marketing support within the Americas and new product launches outside of the Americas.

Cash Flow

Cash flow from operations for the first nine months of 2008 was $328.6 million compared to $354.5 million for the same period in 2007. The decrease reflects increased inventory levels for new product launches and new contract awards with group purchasing organizations, as well as higher trade receivables, which were primarily due to the increased level of sales in the third quarter of 2008 compared to the same period in 2007.

Capital expenditures were $126.9 million for the first nine months of 2008, compared with $128.7 million for the same period in 2007.

2008 Projections

The company has revised its net sales projections for the full year to reflect growth on a constant-currency basis. Full-year net sales are expected to increase in a range of 6 to 7 percent, excluding the impact of foreign exchange.

Projections for full-year 2008 adjusted* diluted earnings per share remain unchanged, and are expected to be between $2.50 and $2.55.

The reconciliation between the projected adjusted* diluted earnings per share and GAAP diluted earnings per share follows:

Diluted earnings per share -- adjusted* $2.50 - $2.55

--------------

Estimated charges related to planned facilities

optimization initiatives (mid-point of an estimated

range of $0.12 to $0.14 per diluted share for 2008) ($0.13)

Estimated integration and other acquisition-related

expenses (high end of an estimated range of $0.10 to

$0.12 per diluted share for 2008) ($0.12)

Estimated $62 million for the amortization of intangibles

related to the Mayne Pharma acquisition ($0.26)

--------------

Diluted earnings per share -- GAAP $1.99 - $2.04

==============

The company continues to project that cash flow from operations in 2008 will be in the $575 million to $625 million range. Depreciation and amortization, excluding amortization of intangibles related to the Mayne Pharma acquisition, are projected to be between $190 million and $200 million. Capital expenditures are now estimated to range between $170 million and $190 million in 2008.

*Use of Non-GAAP Financial Measures

Non-GAAP financial measures used in this press release are referred to as "adjusted" and are reconciled to the most comparable measures calculated in accordance with GAAP in the schedules attached to this release. For more information regarding these non-GAAP financial measures, please see Hospira's Current Report on Form 8-K furnished to the Securities and Exchange Commission on the date of this press release.

Webcast

A conference call for investors and media will be held at 8 a.m. Central time on Wednesday, Nov. 5, 2008. A live webcast of the conference call will be available at http://www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup for receiving the webcast. A replay will be available on the Hospira Web site for 30 days following the call.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, statements regarding the financial impact of the acquisition of Mayne Pharma, and other statements regarding Hospira's goals, strategy, expectations and commitments. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K, and Hospira's subsequent Quarterly Reports on Form 10-Q, which are filed with the Securities and Exchange Commission, and incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

Hospira, Inc.

Condensed Consolidated Statements of Income

(Unaudited)

(dollars and shares in millions, except for per share amounts)

Three Months Ended Nine Months Ended

September 30, September 30,

--------------- % ------------------ %

2008 2007 Change 2008 2007 Change

------ ------ ------ -------- -------- ------

Net sales $925.5 $838.0 10.4 % $2,715.8 $2,490.1 9.1 %

Cost of products

sold 595.5 543.5 9.6 % 1,742.4 1,654.8 5.3 %

------ ------ -------- --------

Gross Profit 330.0 294.5 12.1 % 973.4 835.3 16.5 %

Research and

development 51.7 51.4 0.6 % 160.1 147.5 8.5 %

Acquired

in-process

research and

development - - nm 0.5 84.8 (99.4)%

Selling,

general and

administrative 145.6 136.5 6.7 % 450.7 414.4 8.8 %

------ ------ -------- --------

Income From

Operations 132.7 106.6 24.5 % 362.1 188.6 92.0 %

Interest expense 27.6 34.7 (20.5)% 87.2 102.5 (14.9)%

Other income, net (2.4) (6.2) (61.3)% (6.5) (12.0) (45.8)%

------ ------ -------- --------

Income Before

Income Taxes 107.5 78.1 37.6 % 281.4 98.1 186.9 %

Income tax expense 25.7 18.7 37.4 % 65.1 37.4 74.1 %

------ ------ -------- --------

Net Income $81.8 $59.4 37.7 % $216.3 $60.7 256.3 %

====== ====== ======== ========

Earnings Per

Common Share:

Basic $0.51 $0.38 34.2 % $1.36 $0.39 248.7 %

====== ====== ======== ========

Diluted $0.51 $0.37 37.8 % $1.34 $0.38 252.6 %

====== ====== ======== ========

Weighted Average

Common Shares

Outstanding:

Basic 159.4 157.1 1.5 % 159.1 156.6 1.6 %

====== ====== ======== ========

Diluted 161.6 160.1 0.9 % 161.4 159.5 1.2 %

====== ====== ======== ========

nm = Percent change is not meaningful.

Hospira, Inc.

Reconciliation of Condensed Consolidated Statements of Income

(Unaudited)

(dollars and shares in millions, except per share amounts)

Three Months Ended September 30,

-------------------------------------------------------

2008 2007

-------------------------- --------------------------

GAAP Adjustments Adjusted GAAP Adjustments Adjusted

------ ------ ------ ------ ------ ------

Net sales $925.5 $ - $925.5 $838.0 $ - $838.0

Cost of

products sold 595.5 (25.5)A 570.0 543.5 (22.0)E 521.5

------ ------ ------ ------ ------ ------

Gross Profit 330.0 25.5 355.5 294.5 22.0 316.5

Research and

development 51.7 (0.9)B 50.8 51.4 (0.6)C 50.8

Acquired

in-process

research and

development - - - - - -

Selling,

general and

administrative 145.6 (2.4)C 143.2 136.5 (7.1)C 129.4

------ ------ ------ ------ ------ ------

Income From

Operations 132.7 28.8 161.5 106.6 29.7 136.3

Interest expense 27.6 - 27.6 34.7 - 34.7

Other income,

net (2.4) - (2.4) (6.2) - (6.2)

------ ------ ------ ------ ------ ------

Income Before

Income Taxes 107.5 28.8 136.3 78.1 29.7 107.8

Income tax

expense 25.7 9.1 D 34.8 18.7 10.4 D 29.1

------ ------ ------ ------ ------ ------

Net Income $81.8 $19.7 $101.5 $59.4 $19.3 $78.7

====== ====== ====== ====== ====== ======

Earnings Per

Common Share:

Basic $0.51 $0.13 $0.64 $0.38 $0.12 $0.50

====== ====== ====== ====== ====== ======

Diluted $0.51 $0.12 $0.63 $0.37 $0.12 $0.49

====== ====== ====== ====== ====== ======

Weighted Average

Common Shares

Outstanding:

Basic 159.4 159.4 159.4 157.1 157.1 157.1

====== ====== ====== ====== ====== ======

Diluted 161.6 161.6 161.6 160.1 160.1 160.1

====== ====== ====== ====== ====== ======

Statistics

(as a % of

Net Sales,

except for

income tax rate)

-----------------

Gross Profit 35.7% 38.4% 35.1% 37.8%

R&D 5.6% 5.5% 6.1% 6.1%

SG&A 15.7% 15.5% 16.3% 15.4%

Income From

Operations 14.3% 17.5% 12.7% 16.3%

Income Before

Income Taxes 11.6% 14.7% 9.3% 12.9%

Net Income 8.8% 11.0% 7.1% 9.4%

Income Tax Rate 23.9% 25.5% 24.0% 27.0%

% Change vs. Prior Year

-----------------------

GAAP Adjusted

------- --------

Net sales 10.4 % 10.4 %

Cost of products sold 9.6 % 9.3 %

Gross Profit 12.1 % 12.3 %

Research and development 0.6 % 0.0 %

Acquired in-process research and

development nm nm

Selling, general and administrative 6.7 % 10.7 %

Income From Operations 24.5 % 18.5 %

Interest expense (20.5)% (20.5)%

Other income, net (61.3)% (61.3)%

Income Before Income Taxes 37.6 % 26.4 %

Income tax expense 37.4 % 19.6 %

Net Income 37.7 % 29.0 %

Earnings Per Common Share:

Basic 34.2 % 28.0 %

Diluted 37.8 % 28.6 %

Weighted Average Common Shares Outstanding:

Basic 1.5 % 1.5 %

Diluted 0.9 % 0.9 %

A -- Includes intangible assets amortization of $15.2 related to the Mayne

Pharma acquisition; charges of $10.0 related to the planned closures

of the Ashland, OH; Montreal, Canada; North Chicago, IL; and Morgan

Hill, CA facilities as well as charges to limit, and transfer, R&D

facility operations related to brain-function monitoring devices as

part of Hospira's facilities optimization initiatives; a gain on the

sale of the Montreal, Canada manufacturing plant ($2.5); and Mayne

Pharma integration and other acquisition-related charges of $2.8.

B -- Includes integration and other acquisition-related charges of $0.2

and facilities optimization initiatives of $0.7.

C -- Mayne Pharma Integration and other acquisition-related charges.

D -- Reflects the tax effect of the above adjustments.

E -- Includes intangible assets amortization of $13.4 related to the Mayne

Pharma acquisition; charges of $8.0 related to the planned closures

of the Donegal, Ireland; Ashland, OH; Montreal, Canada; and North

Chicago, IL facilities as part of Hospira's facilities optimization

initiatives; and Mayne Pharma integration charges of $0.6.

nm = Percent change is not meaningful.

Hospira, Inc.

Reconciliation of Condensed Consolidated Statements of Income

(Unaudited)

(dollars and shares in millions, except per share amounts)

Nine Months Ended September 30,

---------------------------------------------------------

2008 2007

----------------------------- --------------------------

GAAP Adjustments Adjusted GAAP Adjustments Adjusted

-------- ------ ------- ------- ------ -------

Net sales $2,715.8 $ - $2,715.8 $2,490.1 $ - $2,490.1

Cost of

products sold 1,742.4 (76.7)A 1,665.7 1,654.8 (126.1)F 1,528.7

-------- ------ ------- ------- ------ -------

Gross Profit 973.4 76.7 1,050.1 835.3 126.1 961.4

Research and

development 160.1 (2.8)B 157.3 147.5 (1.3)D 146.2

Acquired

in-process

research and

development 0.5 (0.5)C - 84.8 (84.8)C -

Selling,

general and

administrative 450.7 (16.8)D 433.9 414.4 (25.2)D 389.2

-------- ------ ------- ------- ------ -------

Income From

Operations 362.1 96.8 458.9 188.6 237.4 426.0

Interest expense 87.2 - 87.2 102.5 (2.2)G 100.3

Other income,

net (6.5) - (6.5) (12.0) (5.7)H (17.7)

-------- ------ ------- ------- ------ -------

Income Before

Income Taxes 281.4 96.8 378.2 98.1 245.3 343.4

Income tax

expense 65.1 31.3 E 96.4 37.4 55.3 E 92.7

-------- ------ ------- ------- ------ -------

Net Income $216.3 $65.5 $281.8 $60.7 $190.0 $250.7

======== ====== ======= ======= ====== =======

Earnings Per

Common Share:

Basic $1.36 $0.41 $1.77 $0.39 $1.21 $1.60

======== ====== ======= ======= ====== =======

Diluted $1.34 $0.41 $1.75 $0.38 $1.19 $1.57

======== ====== ======= ======= ====== =======

Weighted Average

Common Shares

Outstanding:

Basic 159.1 159.1 159.1 156.6 156.6 156.6

======== ====== ======= ======= ====== =======

Diluted 161.4 161.4 161.4 159.5 159.5 159.5

======== ====== ======= ======= ====== =======

Statistics

(as a % of

Net Sales,

except for

income tax rate)

-----------------

Gross Profit 35.8% 38.7% 33.5% 38.6%

R&D 5.9% 5.8% 5.9% 5.9%

SG&A 16.6% 16.0% 16.6% 15.6%

Income From

Operations 13.3% 16.9% 7.6% 17.1%

Income Before

Income Taxes 10.4% 13.9% 3.9% 13.8%

Net Income 8.0% 10.4% 2.4% 10.1%

Income Tax Rate 23.1% 25.5% 38.1% 27.0%

% Change vs. Prior Year

-----------------------

GAAP Adjusted

------- --------

Net sales 9.1 % 9.1 %

Cost of products sold 5.3 % 9.0 %

Gross Profit 16.5 % 9.2 %

Research and development 8.5 % 7.6 %

Acquired in-process research and

development (99.4)% nm

Selling, general and administrative 8.8 % 11.5 %

Income From Operations 92.0 % 7.7 %

Interest expense (14.9)% (13.1)%

Other income, net (45.8)% (63.3)%

Income Before Income Taxes 186.9 % 10.1 %

Income tax expense 74.1 % 4.0 %

Net Income 256.3 % 12.4 %

Earnings Per Common Share:

Basic 248.7 % 10.6 %

Diluted 252.6 % 11.5 %

Weighted Average Common Shares Outstanding:

Basic 1.6 % 1.6 %

Diluted 1.2 % 1.2 %

A -- Includes intangible assets amortization of $46.8 related to the Mayne

Pharma acquisition; charges of $26.6 related to the planned closures

of the Ashland, OH; Montreal, Canada; North Chicago, IL; and Morgan

Hill, CA facilities as well as charges to limit, and transfer, R&D

facility operations related to brain-function monitoring devices as

part of Hospira's facilities optimization initiatives; a gain on the

sale of the Montreal, Canada manufacturing plant ($2.5); and Mayne

Pharma integration and other acquisition-related charges of $5.8.

B -- Includes Mayne Pharma integration and other acquisition-related

charges of $1.0 and facilities optimization initiatives of $1.8.

C -- Acquired in-process research and development.

D -- Mayne Pharma integration and other acquisition-related charges.

E -- Reflects the tax effect of the above adjustments.

F -- Includes inventory step-up charge of $53.1 and intangible assets

amortization of $35.0 related to the Mayne Pharma acquisition;

charges of $33.4 related to the planned closures of the Donegal,

Ireland; Ashland, OH; Montreal, Canada; and North Chicago, IL

facilities as part of Hospira's facilities optimization initiatives;

a reduction of the obligation associated with the sale of the Salt

Lake City, UT manufacturing plant to ICU Medical ($1.6); and Mayne

Pharma integration charges of $6.2.

G -- Other acquisition-related cost: bridge loan fees incurred as a result

of the Mayne Pharma acquisition expensed upon refinancing of loan

during the first quarter of 2007.

H -- Other acquisition-related cost: foreign exchange losses related to

the Mayne Pharma acquisition.

nm = Percent change is not meaningful.

Hospira, Inc.

Reconciliation of Diluted Earnings Per Share

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

------------------- --------------------

2008 2007 2008 2007

------ ------ ------ ------

Diluted Earnings Per

Share - GAAP $0.51 $0.37 $1.34 $0.38

Adjustments:

Mayne Pharma acquisition

related:

Acquired in-process

research and

development - - - 0.53

Inventory step-up

charge - - - 0.23

Integration and

other acquisition-

related charges 0.03 0.03 0.11 0.16

Intangible assets

amortization 0.06 0.06 0.20 0.15

Charges related to

facilities optimization

initiatives 0.04 0.03 0.11 0.13

Gain on the sale of the

Montreal, Canada

manufacturing plant (0.01) - (0.01) -

Reduction of obligation

associated with the

sale of the Salt Lake

City, UT manufacturing

plant - - - (0.01)

------ ------ ------ ------

Subtotal of Adjustments 0.12 0.12 0.41 1.19

Diluted Earnings Per

Share - Adjusted $0.63 $0.49 $1.75 $1.57

====== ====== ====== ======

Hospira, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(dollars in millions)

September 30, December 31,

Assets 2008 2007

-------- --------

Current Assets:

Cash and cash equivalents $287.4 $241.1

Trade receivables, less allowances of

$12.6 in 2008 and $14.1 in 2007 618.7 559.0

Inventories 854.8 766.6

Deferred income taxes 156.7 176.7

Prepaid expenses 29.0 23.8

Other receivables 71.7 73.8

-------- --------

Total Current Assets 2,018.3 1,841.0

-------- --------

Property and equipment, net 1,226.4 1,276.9

Intangible assets, net 473.3 554.0

Goodwill 1,181.4 1,240.9

Deferred income taxes 65.9 79.4

Investments 47.6 23.7

Other assets 54.3 68.8

-------- --------

Total Assets $5,067.2 $5,084.7

======== ========

Liabilities and Shareholders' Equity

Current Liabilities:

Short-term borrowings $328.8 $58.5

Trade accounts payable 193.3 190.3

Salaries, wages and commissions 141.6 143.6

Deferred income taxes - 8.4

Other accrued liabilities 305.6 393.5

-------- --------

Total Current Liabilities 969.3 794.3

-------- --------

Long-term debt 1,832.6 2,184.4

Deferred income taxes 32.7 50.7

Post-retirement obligations and other long-

term liabilities 335.0 310.1

Commitments and Contingencies -------- --------

Total Shareholders' Equity 1,897.6 1,745.2

-------- --------

Total Liabilities and Shareholders' Equity $5,067.2 $5,084.7

======== ========

Hospira, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(dollars in millions)

Nine Months Ended September 30,

-------------------------------

2008 2007

------- -------

Cash Flow From Operating Activities:

Net income $216.3 $60.7

Adjustments to reconcile net income to net

cash from operating activities --

Depreciation 141.2 136.2

Amortization of intangibles 51.1 37.1

Write-off of acquired in-process research

and development 0.5 84.8

Step-up value of acquired inventories sold - 53.1

Stock-based compensation expense 33.2 31.6

Net gains on sales of assets (3.0) (2.9)

Changes in assets and liabilities --

Trade receivables (75.8) (42.3)

Inventories (107.6) (3.4)

Prepaid expenses and other assets 4.1 5.4

Trade accounts payable 7.3 4.8

Other liabilities 37.1 (31.0)

Other, net 24.2 20.4

------- -------

Net Cash Provided by Operating Activities 328.6 354.5

------- -------

Cash Flow From Investing Activities:

Capital expenditures (including instruments

placed with or leased to customers) (126.9) (128.7)

Acquisitions, net of cash acquired, including

payments for deferred consideration (22.2) (1,963.2)

Purchases of intangibles and other investments (49.6) -

(Purchases) Sales of marketable securities (24.5) 0.6

Settlements of foreign currency contracts - (55.7)

Proceeds from dispositions of product rights - 13.8

Proceeds from disposal of facilities 0.8 -

------- -------

Net Cash Used in Investing Activities (222.4) (2,133.2)

------- -------

Cash Flow From Financing Activities:

Issuance of long-term debt, net of fees paid - 3,336.2

Repayment of long-term debt (90.1) (1,700.1)

Other borrowings, net 8.5 (0.3)

Excess tax benefit from stock-based

compensation arrangements 1.0 0.9

Proceeds from stock options exercised 27.4 40.4

------- -------

Net Cash (Used in) Provided by Financing

Activities (53.2) 1,677.1

------- -------

Effect of exchange rate changes on cash

and cash equivalents (6.7) 16.0

------- -------

Net change in cash and cash equivalents 46.3 (85.6)

Cash and cash equivalents at beginning of period 241.1 322.0

------- -------

Cash and cash equivalents at end of period $287.4 $236.4

======= =======

Supplemental Cash Flow Information:

Cash paid during the period --

Interest $96.6 $57.7

Income taxes, net $8.6 $57.6

Hospira, Inc.

Net Sales by Product Line

(Unaudited)

(dollars in millions)

Three Months Ended September 30,

-------------------------------------------------

% Change at % Change at

Actual Constant

2008 2007 Rates Rates

------ ------ ------- -------

Americas --

Pharmaceuticals

Specialty

Injectables $341.1 $299.9 13.7 % 13.5 %

Other Pharma 129.8 131.3 (1.1)% (1.4)%

------ ------

470.9 431.2 9.2 % 9.0 %

Devices

Medication

Management Systems 138.5 123.0 12.6 % 11.9 %

Other Devices 96.3 90.5 6.4 % 6.2 %

------ ------

234.8 213.5 10.0 % 9.5 %

Total Americas 705.7 644.7 9.5 % 9.2 %

Europe, Middle East &

Africa --

Pharmaceuticals

Specialty

Injectables 67.5 65.0 3.8 % (2.3)%

Other Pharma 41.3 37.8 9.3 % 5.4 %

------ ------

108.8 102.8 5.8 % 0.5 %

Devices

Medication

Management Systems 19.6 16.1 21.7 % 12.5 %

Other Devices 18.2 14.9 22.1 % 13.1 %

------ ------

37.8 31.0 21.9 % 12.8 %

Total Europe, Middle

East & Africa 146.6 133.8 9.6 % 3.4 %

Asia Pacific --

Pharmaceuticals

Specialty

Injectables 57.3 45.7 25.4 % 19.8 %

Other Pharma 4.5 4.2 7.1 % 1.2 %

------ ------

61.8 49.9 23.8 % 18.2 %

Devices

Medication

Management Systems 4.8 4.0 20.0 % 14.7 %

Other Devices 6.6 5.6 17.9 % 10.5 %

------ ------

11.4 9.6 18.8 % 12.3 %

Total Asia Pacific 73.2 59.5 23.0 % 17.3 %

------ ------

Net Sales $925.5 $838.0 10.4 % 8.8 %

====== ======

Nine Months Ended September 30,

--------------------------------------------------

% Change at % Change at

Actual Constant

2008 2007 Rates Rates

-------- -------- ------- -------

Americas --

Pharmaceuticals

Specialty

Injectables $981.7 $891.2 10.2 % 9.4 %

Other Pharma 374.4 393.6 (4.9)% (5.5)%

-------- --------

1,356.1 1,284.8 5.5 % 4.7 %

Devices

Medication

Management Systems 418.3 372.2 12.4 % 11.1 %

Other Devices 282.7 273.4 3.4 % 2.4 %

-------- --------

701.0 645.6 8.6 % 7.4 %

Total Americas 2,057.1 1,930.4 6.6 % 5.7 %

Europe, Middle East &

Africa --

Pharmaceuticals

Specialty

Injectables 224.2 184.3 21.6 % 11.0 %

Other Pharma 120.3 111.3 8.1 % 0.1 %

-------- --------

344.5 295.6 16.5 % 6.9 %

Devices

Medication

Management Systems 59.3 49.8 19.1 % 6.4 %

Other Devices 52.2 51.1 2.2 % (8.4)%

-------- --------

111.5 100.9 10.5 % (1.1)%

Total Europe, Middle

East & Africa 456.0 396.5 15.0 % 4.9 %

Asia Pacific --

Pharmaceuticals

Specialty

Injectables 155.3 121.6 27.7 % 16.5 %

Other Pharma 12.1 10.8 12.0 % (0.2)%

-------- --------

167.4 132.4 26.4 % 15.1 %

Devices

Medication

Management Systems 15.5 12.3 26.0 % 16.6 %

Other Devices 19.8 18.5 7.0 % (3.1)%

-------- --------

35.3 30.8 14.6 % 4.8 %

Total Asia Pacific 202.7 163.2 24.2 % 13.2 %

-------- --------

Net Sales $2,715.8 $2,490.1 9.1 % 6.1 %

======== ========

Notes:

Specialty Injectables include generic injectables and proprietary

specialty injectables. Other Pharmaceuticals include large volume IV

solutions, nutritionals and contract manufacturing services (including

former "Sales to Abbott"). Medication Management Systems include infusion

pumps, related software, services and administration sets. Other Devices

include gravity administration sets, critical care products, and other

device products.

Net sales for the nine months ended September 30, 2008 and 2007,

include nine and eight months, respectively, of Mayne Pharma net sales.

Hospira, Inc.

Segment Information

(Unaudited)

(dollars in millions)

Three Months Ended September 30,

----------------------------------------------------------

Net Sales Income from Operations

----------------- ------------------

% %

2008 2007 Change 2008 2007 Change

------ ------ ------ ------ ------ ------

Americas $705.7 $644.7 9.5 % $151.1 A $127.2 A 18.8 %

Europe,

Middle East

& Africa 146.6 133.8 9.6 % 4.4 B 1.8 B 144.4 %

Asia Pacific 73.2 59.5 23.0 % 6.4 C 5.6 C 14.3 %

------ ------ ------ ------

Total

reportable

segments $925.5 $838.0 10.4 % 161.9 134.6 20.3 %

====== ======

Corporate

functions (20.5)D (19.9)D 3.0 %

Stock-based

compensation (8.7) (8.1) 7.4 %

------ ------

Income from

operations 132.7 106.6 24.5 %

Interest

expense and

other income,

net (25.2)E (28.5)E (11.6)%

------ ------

Income before

income taxes $107.5 $78.1 37.6 %

====== ======

Included in the reported Income before

income taxes above, are the following charges:

A -- Americas

Mayne Pharma acquisition related:

Acquired in-process research and

development $ - $ -

Inventories step-up charge - -

Integration and other acquisition-

related charges 1.0 0.9

Intangible assets amortization 4.8 3.4

Charges related to facilities

optimization initiatives 10.7 7.6

Integration and other acquisition-

related charges (0.2) -

Acquired in-process research and

development - -

Gain on the sale of the Montreal,

Canada manufacturing plant (2.5) -

Reduction of obligation associated with

the sale of the Salt Lake City, UT

manufacturing plant - -

------ ------

Total Americas 13.8 11.9

B -- Europe, Middle East & Africa

Mayne Pharma acquisition related:

Acquired in-process research and

development - -

Inventories step-up charge - -

Integration and other acquisition-

related charges 0.7 1.1

Intangible assets amortization 5.8 5.7

Charges related to facilities

optimization initiatives - 0.4

------ ------

Total Europe, Middle East & Africa 6.5 7.2

C -- Asia Pacific

Mayne Pharma acquisition related:

Inventories step-up charge - -

Integration and other acquisition-

related charges 2.1 0.9

Intangible assets amortization 4.6 4.3

Charges related to facilities

optimization initiatives - -

Integration and other acquisition-

related charges 0.8 0.4

------ ------

Total Asia Pacific 7.5 5.6

D -- Corporate functions

Integration and other acquisition-

related charges 1.0 5.0

------ ------

Total Corporate functions 1.0 5.0

E -- Interest expense and other

income, net

Integration and other acquisition-

related charges - -

------ ------

Total Interest expense and other

income, net - -

------ ------

Total $28.8 $29.7

====== ======

Hospira, Inc.

Segment Information

(Unaudited)

(dollars in millions)

Nine Months Ended September 30,

----------------------------------------------------------

Net Sales Income from Operations

------------------- -------------------

% %

2008 2007 Change 2008 2007 Change

-------- -------- ------ ------ ------ ------

Americas $2,057.1 $1,930.4 6.6 % $426.0 A $301.4 A 41.3 %

Europe,

Middle East

& Africa 456.0 396.5 15.0 % 10.7 B (15.4)B 169.5 %

Asia Pacific 202.7 163.2 24.2 % 13.6 C (8.4)C 261.9 %

-------- -------- ------ ------

Total

reportable

segments $2,715.8 $2,490.1 9.1 % 450.3 277.6 62.2 %

======== ========

Corporate

functions (55.0)D (57.4)D (4.2)%

Stock-based

compensation (33.2) (31.6) 5.1 %

------ ------

Income from

operations 362.1 188.6 92.0 %

Interest

expense and

other income,

net (80.7)E (90.5)E (10.8)%

------ ------

Income before

income taxes $281.4 $98.1 186.9 %

====== ======

Included in the reported Income before

income taxes above, are the following charges:

A -- Americas

Mayne Pharma acquisition related:

Acquired in-process research and

development $ - $66.2

Inventories step-up charge - 10.0

Integration and other acquisition-

related charges 2.1 13.0

Intangible assets amortization 15.0 8.8

Charges related to facilities

optimization initiatives 28.4 32.1

Integration and other acquisition-

related charges - -

Acquired in-process research and

development 0.5 -

Gain on the sale of the Montreal,

Canada manufacturing plant (2.5) -

Reduction of obligation associated with

the sale of the Salt Lake City, UT

manufacturing plant - (1.6)

------ ------

Total Americas 43.5 128.5

B -- Europe, Middle East & Africa

Mayne Pharma acquisition related:

Acquired in-process research and

development - 18.6

Inventories step-up charge - 18.0

Integration and other acquisition-

related charges 10.1 2.1

Intangible assets amortization 17.7 14.9

Charges related to facilities

optimization initiatives - 1.3

------ ------

Total Europe, Middle East & Africa 27.8 54.9

C -- Asia Pacific

Mayne Pharma acquisition related:

Inventories step-up charge - 25.1

Integration and other acquisition-

related charges 5.5 1.9

Intangible assets amortization 14.1 11.3

Charges related to facilities

optimization initiatives - -

Integration and other acquisition-

related charges 1.2 0.4

------ ------

Total Asia Pacific 20.8 38.7

D -- Corporate functions

Integration and other acquisition-

related charges 4.7 15.3

------ ------

Total Corporate functions 4.7 15.3

E -- Interest expense and other

income, net

Integration and other acquisition-

related charges - 7.9

------ ------

Total Interest expense and other

income, net - 7.9

------ ------

Total $96.8 $245.3

====== ======


'/>"/>
SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved


Related medicine news :

1. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
2. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
3. Hospira Announces New Contracts With Premier Purchasing Partners for Infusion Devices, Solutions And Equipment
4. Hospira Reports Second-Quarter 2008 Results
5. Hospira Hosts Conference Call for Second-Quarter 2008 Earnings
6. Hospira Highlights Strategic Initiatives at Its 2008 Annual Meeting of Shareholders
7. Hospira to Present at the Bank of America 2008 Health Care Conference on May 14
8. Hospira Acquires Sculptor
9. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
10. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
11. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... The book, “Computers Should Just Work!”, provides a ... ask your IT consultant before signing a contract and how to spot an incompetent ... companies relying heavily on e-mail and technology, it’s more important than ever to make ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... (WMIS), known as the World Molecular Imaging Congress (WMIC), will be held in ... the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... , a full-service health care communications company offering education, research and medical ... for practitioners and specialists working in infectious diseases. , As the all-inclusive ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , ... recently partnered with Heart City Health Center to improve access to ... Heart City Health Center has provided the Elkhart community with access to high ...
(Date:2/10/2016)... Glendale, CA (PRWEB) , ... February 10, 2016 , ... ... can be harder to find. Unfortunately, this can leave patients with dental emergencies at ... Glendale , is now offering emergency dental care. , Common dental emergencies include:, ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the ... an agreement with the University of Pittsburgh for ... standard animal models of ocular virus infections. ... Romanowski has extensive experience in ocular virus infections ... Eric Romanowski , Research Director. Dr. Romanowski has ...
(Date:2/11/2016)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) (the ... of a once-daily, oral therapy for the treatment of ... Dr. Maya Halpern , has notified the Company that ... and from its Board of Directors effective as of ... Allen Baharaff . Mr. Baharaff continued, "While ...
(Date:2/11/2016)... 11, 2016 Indiso ltd , a ... of pulmonary and respiratory diseases announced today positive results ... COPD and asthma patients show improvements in respiratory functions ... --> Upper and lower respiratory tract ... developed world and reached epidemic level. Increasing number of ...
Breaking Medicine Technology: